| Title |
Utility and safety of procalcitonin in an antimicrobial stewardship program (ASP) in patients with malignancies
|
|---|---|
| Published in |
European Journal of Clinical Microbiology & Infectious Diseases, June 2012
|
| DOI | 10.1007/s10096-012-1662-2 |
| Pubmed ID | |
| Authors |
Y. X. Liew, W. Lee, Y. Y. Cai, J. Teo, S. S.-L. Tang, R. W.-Q. Ong, C. L.-L. Lim, P. B. Lingegowda, A. L.-H. Kwa, M. P. Chlebicki |
| Abstract |
As data on procalcitonin utility in antibiotics discontinuation [under an antimicrobial stewardship program (ASP)] in patients with malignancies are lacking, we aimed to evaluate the utility of procalcitonin in an ASP in patients with malignancies. We conducted a retrospective review of the ASP database of all patients with malignancies in whom at least one procalcitonin level was taken and our ASP had recommended changes in carbapenem regimen, from January to December 2011. We compared clinical outcomes between two groups of patients: patients whose physicians accepted and those whose physicians rejected ASP interventions. There were 749 carbapenem cases reviewed. Ninety-nine were suggested to either de-escalate, discontinue antibiotics, or narrow the spectrum of empiric treatment, based on procalcitonin trends. While there was no statistical difference in the mortality within 30 days post-ASP intervention (accepted: 8/65 patients vs. rejected: 9/34 patients; p = 0.076), the median duration of carbapenem therapy was significantly shorter (5 vs. 7 days; p = 0.002). Procalcitonin use safely facilitates decisions on antibiotics discontinuation and de-escalation in patients with malignancies in the ASP. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 3% |
| Unknown | 34 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 23% |
| Other | 5 | 14% |
| Student > Bachelor | 3 | 9% |
| Professor > Associate Professor | 3 | 9% |
| Professor | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 10 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Nursing and Health Professions | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 4 | 11% |
| Unknown | 11 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2012.
All research outputs
#18,308,895
of 22,668,244 outputs
Outputs from European Journal of Clinical Microbiology & Infectious Diseases
#2,160
of 2,768 outputs
Outputs of similar age
#128,574
of 166,794 outputs
Outputs of similar age from European Journal of Clinical Microbiology & Infectious Diseases
#19
of 24 outputs
Altmetric has tracked 22,668,244 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,768 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,794 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.